RxDoctor Payments Data

Erik Gottschling

Nurse Practitioner · Clearwater, FLNPI 1063146082

Payments from drug & device makers

$955in general payments, 2019–2025

Across 34 payments — averaging $28.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$278
  • GSK$278
  • AstraZeneca$183
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$87
  • Exact Sciences$59
  • Pfizer$29
  • plus $43 from 2 others

What the payments were for

  • Food & beverage$955100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$955 in reported general payments places this provider in the 70th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$7,478
Medicare patients
23
Services billed
99

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$29,496
MyrbetriqMirabegron11$12,745
LantusInsulin Glargine,hum.Rec.Anlog30$5,376
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm11$2,728
Novolin RInsulin Regular, Human27$2,375
Albuterol Sulfate HfaAlbuterol Sulfate76$2,364
Levothyroxine Sodium161$1,268
Rosuvastatin Calcium74$1,244
Gabapentin86$1,025
Atorvastatin Calcium138$850
Losartan Potassium111$811
Testosterone Cypionate11$798
Fluticasone Propionate66$644
Pantoprazole Sodium76$636
Diclofenac Sodium26$558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$29,49620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →